Gangbuk Samsung Hospital Uses Lunit AI... "Supplied to 60% of Tertiary Hospitals"

Medical AI company Lunit announced on the 1st that it has signed a supply contract for the breast mammography AI imaging diagnostic solution ‘Lunit Insight MMG’ with Kangbuk Samsung Hospital. This means that Lunit Insight products are now used in 60% (28 out of 47) of the top-tier general hospitals in Korea.

Lunit's AI imaging analysis solution for mammography, 'Lunit Insight MMG'
[Photo by Lunit]

Lunit Insight MMG is a solution that analyzes breast mammography images using deep learning-based AI technology to quickly detect and visualize suspicious areas of breast cancer. It especially helps accurate diagnosis by minimizing reading errors that may occur depending on the density of breast tissue.

Kangbuk Samsung Hospital, which decided to introduce Lunit’s product this time, established the Future Healthcare Headquarters this year and is accelerating its leap to become a leading hospital in ICT convergence digital healthcare. The introduction of this AI solution also aims to provide innovative digital medical services by integrating AI into the breast cancer screening and treatment process. Lunit plans to continuously provide education and technical support related to the AI solution to the medical staff of Kangbuk Samsung Hospital to support effective utilization.

Furthermore, Lunit plans to expand the supply of AI solutions to major top-tier general hospitals in Korea based on this supply. The company intends to actively work on continuously proving the practical value of AI in medical settings and broadening the base of the medical AI industry.

Seobum Seok, CEO of Lunit, said, "The introduction of Lunit AI to major top-tier general hospitals like Kangbuk Samsung Hospital is an important milestone in the spread of medical AI technology," adding, "As the role of AI in the medical field gradually expands, we will continue to develop more sophisticated and reliable AI solutions through continuous research and development (R&D) investment and clinical research."